# Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients.

> **NCT00828958** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 53 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Risperidone long-acting injectable

## Key facts

- **NCT ID:** NCT00828958
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** —
- **Final completion:** 2006-09
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2011-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00828958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00828958, "Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00828958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*